Fem-Dophilus contains two patented and clinically documented probiotic strains, Lacticaseibacillus rhamnosus GR-1 and Limosilactobacillus reuteri RC-14, discovered and developed by Dr. Gregor Reid and Dr. Andrew Bruce at Urex Biotech. Over 25 years of research supports the oral use of GR-1 and RC-14 to colonize and promote healthy vaginal and urinary tract health. A special manufacturing process protects the probiotic strains in Fem-Dophilus from stomach acid and enhances probiotic bacterial survival to the lower intestine.